EUVIMEDEUVIMED entdecken
Open Access

Preclinical Evaluation of [ 212 Pb]Pb-ADVC001: A Prostate-Specific Membrane Antigen–Targeted α-Therapy for Prostate Cancer

Feifei Liu, Melissa E Monterosso, Didier Boucher, Stelle Shakti, Kwong Ching Li, Chanwoo Kim, Amber Prior, Abby Sydes, Amelia T Soderholm, Nicholas Fletcher, Dewan Akhter, Kristofer Thurecht und 11 weitere

Journal of Nuclear Medicine · 2025

DOI: 10.2967/jnumed.125.269707 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Feifei Liu und 22 weiteren Autor:innen. Beteiligte Einrichtung: AdvanCell Pty Ltd., Sydney, New South Wales, Australia; and. Hauptthemen laut MEDLINE: Glutamate Carboxypeptidase II, Alpha Particles, Prostatic Neoplasms, Lead Radioisotopes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate-specific membrane antigen (PSMA)-directed radiopharmaceutical therapies continue to improve treatment outcomes in patients with metastatic castration-resistant prostate cancer. Here, we report the in vitro and in vivo characterization of a PSMA-targeted therapy (ADVC001) specifically designed for targeted α-therapy with 212Pb.

Methods

The binding affinity to PSMA was determined by PSMA enzymatic assays and by radioligand binding assays using PSMA-high prostate cancer (PC) cells. In vitro cytotoxicity against PC cell lines with high and medium PSMA expression was evaluated using clonogenic, metabolic, and imaging-based cytotoxic assays. Pharmacokinetics and biodistribution were assessed using PSMA-high subcutaneous tumor xenografts. In vivo single-dose and multidose efficacy was assessed in subcutaneous PC xenograft models expressing various levels of PSMA.

Results

A high binding affinity to PSMA was observed for ADVC001 with nanomolar inhibitory concentration of 50% values. In cellular assays, [212Pb]Pb-ADVC001 (212Pb-ADVC001 hereafter for simplicity) exhibited specific cytotoxic activity against PSMA-expressing cells with nanomolar effective concentration of 50% values. In vivo biodistribution of 212Pb-ADVC001 in the PC3-PIP xenograft model revealed rapid and persistent tumor uptake, fast renal clearance, and low retention in normal tissues. Single-dose efficacy studies of 212Pb-ADVC001 (0.46 MBq) showed improved survival compared with [177Lu]Lu-PSMA-I&T (177Lu-PSMA-I&T hereafter for simplicity) (20 MBq) treatment. In a multidose experiment, 2 doses of 212Pb-ADVC001 (0.5 MBq) significantly increased median survival (86 d vs. 45.5 d, P < 0.05) compared with 2 doses of 177Lu-PSMA-I&T (15 MBq). Treatment with 212Pb-ADVC001 (0.5 MBq) after initial 177Lu-PSMA-I&T (15 MBq) relapse showed an enhanced survival benefit (59.5 d). In a C4-2 xenograft model with medium-level PSMA expression, single doses of 0.3, 0.8, and 1.1 MBq of 212Pb-ADVC001 significantly extended median survival to 34, 57, and 62.5 d, compared with untreated cohorts (16 d). All treatments were well tolerated.

Conclusion

The preclinical results support the clinical development of 212Pb-ADVC001 as a targeted α-therapy for the treatment of patients with PC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glutamate Carboxypeptidase IIAlpha ParticlesProstatic NeoplasmsLead RadioisotopesAntigens, SurfaceMolecular Targeted TherapyMaleHumansAnimalsMiceCell Line, TumorTissue DistributionXenograft Model Antitumor AssaysRadiopharmaceuticalsDrug Evaluation, Preclinical

Stichwörter der Autor:innen

212PbPSMApreclinicalprostate cancertargeted α-therapytheranostics

Substanzen

Glutamate Carboxypeptidase IILead RadioisotopesAntigens, SurfaceFOLH1 protein, humanLead-212Radiopharmaceuticals

Autor:innen und Institutionen

  • AdvanCell Pty Ltd., Sydney, New South Wales, Australia; and.
  • Centre for Advanced Imaging and Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland, Australia.
  • AdvanCell Pty Ltd., Sydney, New South Wales, Australia; and thomas.kryza@advancell.com.au gary.li@advancell.com.au.

Zitieren

APA

Liu, F., Monterosso, M. E., Boucher, D., Shakti, S., Li, K. C., Kim, C., Prior, A., Sydes, A., Soderholm, A. T., Fletcher, N., Akhter, D., Thurecht, K., Tieu, W., Kuan, K., Horsfall, A., Kumar, S., Koehbach, J., Hammond, E., Karmann, A., …, & Kryza, T. (2025). Preclinical Evaluation of [ 212 Pb]Pb-ADVC001: A Prostate-Specific Membrane Antigen–Targeted α-Therapy for Prostate Cancer. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.269707

Vancouver

Liu F, Monterosso ME, Boucher D, Shakti S, Li KC, Kim C, et al. Preclinical Evaluation of [ 212 Pb]Pb-ADVC001: A Prostate-Specific Membrane Antigen–Targeted α-Therapy for Prostate Cancer. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.125.269707

BibTeX
@article{Liu2025,
  author = {Liu, Feifei and Monterosso, Melissa E and Boucher, Didier and Shakti, Stelle and Li, Kwong Ching and Kim, Chanwoo and Prior, Amber and Sydes, Abby and Soderholm, Amelia T and Fletcher, Nicholas and Akhter, Dewan and Thurecht, Kristofer and Tieu, William and Kuan, Kevin and Horsfall, Aimee and Kumar, Saawan and Koehbach, Johannes and Hammond, Edward and Karmann, Anna and Rose, Stephen and Li, Gary and Puttick, Simon and Kryza, Thomas},
  title = {Preclinical Evaluation of [ 212 Pb]Pb-ADVC001: A Prostate-Specific Membrane Antigen–Targeted α-Therapy for Prostate Cancer},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  doi = {10.2967/jnumed.125.269707}
}
Kostenlos starten →